This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cancer Vaccines: From First-in-Class To Best-in-Class?

NEW YORK, April 9, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Cancer Vaccines: From First-in-Class to Best-in-Class?

This report gives you a new and unique way of stratifying and analyzing the global cancer vaccine pipeline and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?* What is first-in-class in the cancer vaccine pipeline?* Is First-in-Class the Best-in-Class?* Indication expansion opportunities* Drug repositioning opportunities* Which pathways are targeted, by what and how?* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 196 cancer vaccine drugs from within the portfolio of 114 companies world-wide, from Ceased to Marketed. We have identified 137 drug targets, which we have organized into 114 drug target strategies and assessed them in 52 tumor types. Our pipeline analysis has five levels:

1) Target Atlas: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2) First-in-Class to Best-in-Class: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3) Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4) Indication Selection: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

5) Competitive Landscape: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.87 0.18%
FB $102.29 0.37%
GOOG $684.98 0.27%
TSLA $149.55 -0.61%
YHOO $27.12 1.30%


Chart of I:DJI
DOW 15,890.05 +229.87 1.47%
S&P 500 1,854.50 +25.42 1.39%
NASDAQ 4,313.3520 +46.5150 1.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs